S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
New CBOE “special perk” helps traders target income every weekend (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
New CBOE “special perk” helps traders target income every weekend (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
New CBOE “special perk” helps traders target income every weekend (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
New CBOE “special perk” helps traders target income every weekend (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
UN takes no immediate action at emergency meeting on Guyana-Venezuela dispute over oil-rich region

Karuna Therapeutics (KRTX) Earnings Date, Estimates & Call Transcripts

$205.48
-0.77 (-0.37%)
(As of 12/8/2023 ET)
Compare
Today's Range
$200.00
▼
$206.18
50-Day Range
$161.01
▼
$208.80
52-Week Range
$158.38
▼
$245.00
Volume
556,792 shs
Average Volume
269,633 shs
Market Capitalization
$7.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$259.38
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Feb. 22Estimated
Actual EPS
(Nov. 2)
-$3.16 Missed By -$0.42
Consensus EPS
(Nov. 2)
-$2.74
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

KRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Karuna Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20235($3.06)($1.69)($2.60)
Q2 20235($3.17)($1.70)($2.71)
Q3 20235($3.41)($1.68)($2.82)
Q4 20235($3.59)($1.80)($2.98)
FY 202320($13.23)($6.87)($11.11)
Q1 20242($3.33)($3.03)($3.18)
Q2 20243($3.47)($3.18)($3.31)
Q3 20243($3.31)($2.77)($3.02)
Q4 20243($3.31)($2.24)($2.75)
FY 202411($13.42)($11.22)($12.27)
Q1 20251($2.13)($2.13)($2.13)
Q2 20251($1.74)($1.74)($1.74)

KRTX Earnings Date and Information

Karuna Therapeutics last issued its earnings data on November 2nd, 2023. The reported ($3.16) EPS for the quarter, missing the consensus estimate of ($2.74) by $0.42. Karuna Therapeutics has generated ($10.93) earnings per share over the last year (($10.93) diluted earnings per share). Earnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.31) to ($11.28) per share. Karuna Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 22nd, 2024 based off prior year's report dates.

Karuna Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/22/2024
Estimated)		------- 
11/2/2023Q3 2023($2.74)($3.16)($0.42)($3.16)--
8/3/2023Q2 2023($2.76)($2.75)+$0.01($2.75)$0.42 million$0.10 million    
5/4/2023Q1 2023($2.86)($2.80)+$0.06($2.80)-$0.65 million    
2/23/2023Q4 2022($2.26)($2.22)+$0.04($2.22)-$5.30 million
11/3/2022Q3 2022($1.99)($2.38)($0.39)($2.38)$10.00 million$0.08 million
8/8/2022Q2 2022($2.02)($2.17)($0.15)($2.17)-$5.28 million
5/5/2022Q1 2022($2.06)($1.95)+$0.11($1.95)--
2/24/2022Q4 2021($1.52)($0.94)+$0.58($0.94)$5.38 million$36.96 million    
11/4/2021Q3 2021($1.47)($1.72)($0.25)($1.72)--
8/5/2021Q2 2021($1.34)($1.17)+$0.17($1.17)--
5/6/2021Q1 2021($1.14)($1.10)+$0.04($1.10)--  
2/25/2021Q4 2020($0.89)($0.89)-($0.89)--












Karuna Therapeutics Earnings - Frequently Asked Questions

When is Karuna Therapeutics's earnings date?

Karuna Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 22nd, 2024 based off last year's report dates. Learn more on KRTX's earnings history.

Did Karuna Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Karuna Therapeutics (NASDAQ:KRTX) missed the analysts' consensus estimate of ($2.74) by $0.42 with a reported earnings per share (EPS) of ($3.16). Learn more on analysts' earnings estimate vs. KRTX's actual earnings.

How much revenue does Karuna Therapeutics generate each year?

Karuna Therapeutics (NASDAQ:KRTX) has a recorded annual revenue of $5.93 million.

How much profit does Karuna Therapeutics generate each year?

Karuna Therapeutics (NASDAQ:KRTX) has a recorded net income of -$276.34 million. KRTX has generated -$10.93 earnings per share over the last four quarters.

What is Karuna Therapeutics's EPS forecast for next year?

Karuna Therapeutics's earnings are expected to grow from ($11.31) per share to ($11.28) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:KRTX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -